Lyracaine Topical Anesthetic Now Approved for Sale in Canada

AURORA, ON, Oct. 1, 2014 /CNW/ - Prollenium Medical Technologies Inc. is proud to announce that Lyracaine topical anesthetic is now available for sale in Canada. Lyracaine is a fast-acting, clear, topical anesthetic containing a high concentration of Lidocaine (5%). It gently reduces pain by quickly numbing the skin. Lyracaine works within 20-30 minutes and does not require occlusion (a dressing). It can be used for hair removal, laser treatments, injections, filler treatments and removal of warts.

Lyracaine is a member of the Phiderma Anti-Aging skincare line, developed to provide products that have visible and lasting results. Partnerships with leading dermatologists have led to the development of clinically proven products, which are highly effective and suitable for all skin types. The Phiderma line includes vitamin C, full-face retinol, under eye, and an anti-wrinkle complex all supplied in single-use capsules for ease of use and targeted delivery. Phiderma also includes a gentle alternative to injections with Linurase, a topical serum, which combats the appearance of fine lines and wrinkles.

For any questions relating to Phiderma, please contact the Prollenium Customer Service department at 905 508 1469.

For more information, please visit www.phiderma.com or www.prollenium.com.

Prollenium Medical Technologies Inc., founded in 2002, is dedicated to the research, design, manufacture and distribution of implantable polymers in the pharmaceutical/dermatological industry. The company is committed to providing innovative products worldwide that are safe and viable. Flagship product lines include Revanesse^® Hyaluronic Acid Dermal Fillers and Phiderma^® Anti-Aging Skincare.

SOURCE: Prollenium Medical Technologies Inc.

Brittany Edwards, Phone: [phone], Email: [email protected]